Soon, much drug discovery knowledge could be stamped “made in China” — that is, if the new Shanghai Center for Bioinformatics Technology gets off the ground. The center, funded with 80 million Chinese Yuan ($12 million US), aims to export the drug discovery informatics of Chinese scientists to US, European, and Japanese biopharma.

The center is slated to open in November and is located in Shanghai’s life sciences and high-tech sweet-spot, the ten-year old Zhangjiang High-Tech Park.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.